The Contrast Mammography Imaging Screening Trial, or CMIST is comparing two methods of mammography to help women and their doctors decide the best ways to screen for breast cancer in the future.
The CMIST research study will follow women already planned to get three-dimensional (3D) tomosynthesis screening mammography routinely for breast cancer.
The study compares two different types of mammograms used to screen for breast cancer in women who have breast tissue that appears dense on the mammogram. The two types of mammography methods being compared in CMIST are the three-dimensional (3D) tomosynthesis mammography that you are scheduled for and a contrast-enhanced spectral mammography. Our mammography clinic can provide both screening methods. Researchers want to find out which of the two approaches to breast cancer screening is better in the early detection of breast cancers for women with dense breast tissue.
The department of Radiology, Breast Imaging division seeks women, ages 45-74 currently due for an annual screening mammogram for a research study. The purpose of the CMIST study is to compare two methods of mammography to help women and their doctors decide the best ways to screen for breast cancer in the future.
You may be eligible for this study if: you have dense breast tissue as stated on previous mammogram report, are 45-74 years of age and have no history of breast cancer or breast implants.
If you decide to take part in this study, you will be screened for breast cancer with both contrast-enhanced spectral mammography and digital breast tomosynthesis mammography when you enter the study. We will repeat those same tests in one year. Each visit could last up to 3 hours.
Study-related contrast-enhanced spectral mammography provided at no cost.
Participant’s insurance company will be billed for annual screening digital breast tomosynthesis (3D) mammography.